Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT

Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT. Vaderis Therapeutics AG Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom United States of America Canada Europe Maryland

Trial delivers positive results in first ever industry-led clinical trial in Hereditary Haemorrhagic Telangiectasia (HHT)VAD044 showed favourable safety and tolerability, together with exploratory efficacy across key manifestations of the diseaseOngoing Open Label Extension (OLE) data at 6 months show consistent safety, tolerability and continued improvement in bleeding parametersView original content:https://www.prnewswire.co.uk/news-releases/vaderis-announces-positive-clinical-proof-of-concept-trial-in-hht-302230322.html